Compare Novavax Inc (NVAX) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Prudential PLC — how do they compare? Novavax Inc trades at $8.08 (market cap $1.30B), while Prudential PLC trades at $29.07 (market cap $34.25B). The key difference: Prudential PLC is far larger — about 26.3× Novavax Inc's market cap, and Prudential PLC pays a 1.88% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | PUK | |
|---|---|---|
Market Cap | $1.30B | $34.25B |
Sector | Health | Financials |
52-Week High | $11.19 | $33.61 |
52-Week Low | $6.22 | $24.74 |
Enterprise Value | $800.50M | $35.69B |
Dividend Yield | — | 1.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
Prudential (PUK) trades at $28.88, up 2.09% today, showing strong fundamental momentum with revenue growth from $16.21B in 2024 to $27.4B projected for 2025 and consistent earnings beats. The stock appears undervalued with a P/E of 9.21 and P/S of 1.34, while technical indicators show a bearish trend despite neutral oscillators. Recent news highlights JP Morgan's positive catalyst watch ahead of August earnings and strategic moves in Asian markets.
The outlook remains positive given strong profitability (21.15% ROE) and analyst support (50% buy ratings), but risks include regulatory challenges in Japan and China exposure. Current valuation metrics suggest potential upside if earnings momentum continues, though technical resistance near $29 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
